u/No-Calligrapher-1649 ·
Reddit — r/ValueInvesting
· May 13, 2026 at 16:53
· ⬆ 15 pts
· 💬 30 comments
| View on Reddit ↗
AI Summary
Summary
Author is bullish on VEEV (Veeva Systems), citing zero debt, a large cash pile, a $2B buyback, S&P 500 inclusion, a PE ratio at one-third of its historical high, and a monopoly in highly regulated healthcare/drug trial software.
Thesis: VEEV is oversold due to temporary concerns; the upcoming May 27 earnings will confirm strength, aided by the Salesforce “divorce” and successful Vault platform migrations.
Quality assessment: Moderately well-researched DD with specific financial metrics, catalyst dates, and industry moat reasoning, though lacks detailed competitor analysis or downside risks.
Score15
Comments30
Upvote %100%
▶ Full Post Text
It popped up on my radar and the more I research it, the more bullish I am.
Just got added to SP500 so hopefully adds a floor,
0 debt and sitting on a cash mountain with a $2B buyback in place,
Decently outperformed in the last 5 quarters,
Pe sitting at about a third of its max,
Average analyst price target is 60% higher than what it is rn,
Ridiculous moat protection, it directly deals with healthcare and drug trials which have to be highly regulated and Veeva essentially have a monopoly on it which AI isn't going to disrupt any time soon.
Their "divorce" with salesforce if successful will rocket profit margins further and they are successful bringing a lot of clients onto their vault platform.
I truly believe it's crazily oversold and the earnings event on May 27th will hopefully show this. I'm bullish.
VEEV has no debt, $2B buyback, S&P 500 inclusion, and a PE at ~1/3 of historical peak; average analyst target implies 60% upside. These fundamentals, combined with a regulatory moat and upcoming earnings catalyst, suggest the market is mispricing the stock relative to intrinsic value. Long VEEV as a value play with a near-term catalyst (May 27 earnings) and strong operational tailwinds from the Salesforce transition. Earnings miss on May 27; longer-than-expected migration costs; AI disruption or new entrants in clinical trial software; broader tech sell-off.
This Reddit post, published May 13, 2026,
features u/No-Calligrapher-1649
discussing VEEV.
1 trade idea extracted by AI with direction and confidence scoring.